For years, the only weapon Indians had against dengue was a mosquito net, a coil, and luck. Dengue — the "breakbone fever" — has infected over 2.3 lakh Indians annually and killed hundreds, with no vaccine in sight for the average Indian patient. That is about to change. For the first time, a dengue vaccine is arriving in India, and a homegrown one may follow soon after.
If you or a family member has had dengue before — or if you simply live in a dengue-endemic city — this guide explains everything you need to know about the dengue vaccines coming to India, who should consider getting vaccinated, and what these vaccines can and cannot do.
Why a Dengue Vaccine Has Been So Hard to Make
Before understanding the vaccines, you need to understand the unusual biology of dengue — because it is the reason getting a dengue vaccine right is genuinely difficult.
Dengue is caused by four distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. All four circulate in India simultaneously. Infection with one serotype gives you lifelong immunity to that serotype but only short-term cross-protection against the others.
Here is the dangerous twist: a second dengue infection with a different serotype carries a significantly higher risk of severe dengue (dengue haemorrhagic fever and dengue shock syndrome). This happens due to a phenomenon called antibody-dependent enhancement (ADE) — antibodies from your first infection actually help the new virus enter your cells more efficiently.
This means a dengue vaccine must produce balanced immunity against all four serotypes simultaneously. An imbalanced vaccine that generates strong immunity to only two or three serotypes could, theoretically, make someone more vulnerable to the serotypes not well-covered — essentially simulating a first infection and leaving them primed for ADE in a subsequent natural infection.
This biological challenge is precisely why it took decades to develop safe, effective dengue vaccines — and why the two vaccines now arriving in India represent a genuine milestone.
QDENGA: The First Dengue Vaccine Coming to India
QDENGA (also known as TAK-003) is a live-attenuated tetravalent dengue vaccine developed by Japanese pharmaceutical company Takeda. It is the most advanced dengue vaccine now being introduced in India.
How QDENGA Works
QDENGA is built on a backbone of an attenuated DENV-2 strain, into which the structural genes of DENV-1, DENV-3, and DENV-4 have been inserted. This chimeric approach means all four serotypes are represented in a single vaccine. It stimulates your immune system to build antibodies against all four serotypes without causing actual dengue disease.
Efficacy and Safety Data
Results from the large Phase III TIDES trial — involving 20,000 participants across eight countries — showed impressive outcomes:
| Outcome | Efficacy |
|---|---|
| Prevention of symptomatic dengue | ~80% |
| Prevention of severe dengue | ~90% |
| Prevention of dengue hospitalisation | ~85% |
| Long-term follow-up (7 years) | Sustained protection demonstrated |
Crucially, in a 2025 update, Takeda presented data showing QDENGA's protection against all four serotypes holds through 7 years of follow-up — the longest dengue vaccine efficacy data available for any vaccine candidate.
Important note: Unlike the earlier dengue vaccine Dengvaxia (which was only for people with confirmed prior dengue infection and caused harm when given to dengue-naïve individuals), QDENGA can be given to people with or without prior dengue exposure and has not shown a similar safety signal.
QDENGA in India: The Biological E Partnership
In a landmark 2024 collaboration, Takeda partnered with Biological E. Limited, a Hyderabad-based vaccine manufacturer, to produce QDENGA in India. Under this arrangement:
- Biological E. will produce approximately 50 million QDENGA doses annually
- Both single-dose and multi-dose vials will be manufactured
- Multi-dose vials are designed to support large-scale public health immunisation programmes
- Production at scale is expected through 2026 onwards
As of early 2026, the vaccine is advancing through India's regulatory process with the Drug Controller General of India (DCGI).
QDENGA Dosing Schedule
| Parameter | Details |
|---|---|
| Doses | 2 doses |
| Schedule | 0 months and 3 months |
| Route | Subcutaneous injection (0.5 mL per dose) |
| Age eligibility | 4 years and above |
| Prior dengue required | No — can be given regardless of prior infection status |
Expected Cost in India
Internationally, QDENGA costs between $40–$115 per dose (approximately ₹3,300–₹9,500). Takeda has indicated a dual pricing strategy for India, with lower pricing for the public sector. Once available through government immunisation programmes or NVHCP, the cost to patients could be considerably lower. Private market pricing for India has not yet been formally announced.
DengiAll: India's Homegrown Single-Dose Dengue Vaccine
Alongside QDENGA, India is also developing its own dengue vaccine — and it may eventually be the more accessible option for most Indians.
DengiAll is an indigenous dengue vaccine developed by Panacea Biotec in collaboration with ICMR (Indian Council of Medical Research). The vaccine was developed using attenuated strains originally licensed from the US National Institutes of Health (NIH), which Panacea Biotec has further developed since 2006.
What Makes DengiAll Different
The key difference from QDENGA is that DengiAll is designed as a single-dose vaccine. A one-shot dengue vaccine would be transformative for India's public health programmes — reducing logistics complexity and improving coverage, particularly in rural and remote areas.
Early Phase I/II clinical data showed that a single dose generated strong immunogenicity against all four serotypes with a favourable safety profile.
Phase III Trial Status (March 2026)
In January 2026, Panacea Biotec completed Phase III clinical trial enrollment, with 10,335 participants enrolled across multiple sites in India. This is the first Phase III pivotal trial for an indigenous dengue vaccine conducted in India.
The Phase III trial is being conducted under the oversight of ICMR, India's apex medical research body. If results are positive, the vaccine could seek DCGI approval and, subsequently, WHO prequalification for international use.
Expected timeline: A market launch for DengiAll is projected as early as 2027, pending positive trial outcomes and regulatory review.
Who Should Consider Getting the Dengue Vaccine?
While vaccination eligibility will depend on final Indian regulatory guidelines, the current WHO and global guidance suggests dengue vaccination is most beneficial for:
- People who have had confirmed dengue before — Vaccination can help prevent a second, more severe infection
- People living in or frequently travelling to dengue-endemic areas — India's major cities, coastal states, and urban areas with Aedes aegypti mosquito populations
- Children aged 4 years and above in dengue-endemic regions
- Healthcare workers who face repeated exposure during dengue outbreaks
Who Should Be Cautious
- People who have never had dengue and live in low-transmission areas may want to wait for clearer Indian-specific guidelines
- Pregnant and breastfeeding women — safety data is limited; discuss with your doctor
- Immunocompromised individuals — live-attenuated vaccines require careful evaluation
What Vaccination Cannot Replace
Even after vaccination, standard dengue prevention measures remain essential:
- Use of mosquito repellents (DEET or picaridin-based)
- Long-sleeved clothing during daylight hours (Aedes aegypti bites during the day)
- Eliminating stagnant water around your home (coolers, flower pots, old tyres)
- Using mosquito nets for children and infants
Knowing Your Dengue History Before Vaccination
If you are considering vaccination, one of the most practically useful things you can do is know your past dengue infection status. A simple dengue IgG antibody test (costing ₹400–₹900 at labs like SRL, Thyrocare, or Dr. Lal PathLabs) can tell whether you have had dengue before — information your doctor will use to advise you on vaccination.
If you have had dengue before, your prior test reports — NS1 results, platelet count trends, hospitalisation records — are valuable clinical information. By uploading your past dengue reports to MedicalVault, you can keep a permanent, shareable record of your dengue history, which makes it far easier to discuss vaccination with your doctor. Use MedicalVault's trend analysis to also track how key parameters like platelet count have changed during past dengue episodes.
If you have family members who have had dengue, MedicalVault's family sharing feature lets you maintain health records for the whole household — ensuring your spouse, children, and elderly parents all have their dengue histories accessible when vaccination decisions need to be made.
The Broader Picture: India's Dengue Burden
To understand why the dengue vaccine is such welcome news for India, consider the scale of the problem:
- India consistently reports the highest dengue caseload in the world, accounting for around 30–40% of global cases in many years
- Over 2.3 lakh cases and nearly 300 deaths were reported in 2024 alone — and this is believed to be a significant undercount due to limited surveillance and many patients managing dengue at home without testing
- The economic burden is enormous: dengue causes loss of earnings, repeated hospitalisation costs, and productivity losses worth thousands of crores annually
- All four serotypes co-circulate in India — meaning one infection gives you no lasting protection against the other three
Every dengue prevention breakthrough — better tests, better treatments, and now vaccines — directly reduces this massive burden on Indian families.
Understanding Dengue Test Reports Alongside Vaccination
The dengue vaccine does not replace knowing how to interpret dengue test results. Even vaccinated individuals can potentially get dengue (though with reduced severity). If you develop fever after vaccination, you still need the right test at the right time:
- NS1 antigen test — best on Days 1–5 of fever (₹400–₹900 at Indian labs)
- Dengue IgM/IgG antibody test — best from Day 5 onwards (₹500–₹1,200)
- Dengue combo panel — covers all windows in one test (₹700–₹1,800)
For a complete guide on dengue testing, including platelet count monitoring, warning signs of severe dengue, and when to hospitalise, see our dengue test guide.
Key Takeaways
- A dengue vaccine is finally coming to India — QDENGA from Takeda (2-dose, via Biological E.) is advancing through Indian regulatory review as of 2026, and DengiAll, India's own single-dose vaccine developed by ICMR and Panacea Biotec, is in Phase III trials with 10,335 participants enrolled
- QDENGA efficacy is strong: ~80% protection against symptomatic dengue, ~90% against severe dengue, sustained over 7 years — and can be given regardless of prior dengue infection
- DengiAll could be a game-changer: A single-dose indigenous vaccine could transform India's mass immunisation reach, with a potential launch from 2027
- Prior dengue history matters: Know whether you have had dengue before — a dengue IgG test can confirm this — to help your doctor make the right vaccination recommendation
- Vaccination does not replace prevention: Mosquito control, repellents, and eliminating breeding sites remain essential even after vaccination
- Track your dengue health history with MedicalVault — store your past dengue reports, platelet count trends, and vaccination records for a complete, shareable health record accessible to your doctor